Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB (ScreenTB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03350048|
Recruitment Status : Unknown
Verified April 2019 by Prof Gerhard Walzl, University of Stellenbosch.
Recruitment status was: Enrolling by invitation
First Posted : November 22, 2017
Last Update Posted : April 17, 2019
Title: Evaluation of host biomarker-based point-of-care tests for targeted screening for active TB (Screen TB)
Introduction: Tuberculosis (TB) places severe pressure on health care services of the developing world. Despite the introduction of the highly sensitive and specific GeneXpert MTB/RIF (GeneXpert) test  with a potential turn-around time of two hours, many people in high TB prevalence areas still do not have access to efficient TB diagnostic services due to logistical constraints in these settings. A cost effective, rapid, point-of-care screening test with high sensitivity would identify people with a high likelihood for active TB and would prioritize them for testing with more expensive, technically or logistically demanding assays including GeneXpert or liquid culture, facilitating cost-effective diagnostic work-up in resource-limited settings. A serum cytokine signature for active TB disease, discovered in the AE-TBC project, with a sensitivity of 89% (CI 78 - 95%) and specificity of 76% (CI 68 - 83%), will be optimised and utilized in a point-of-care format (TransDot) to rapidly test for TB disease in symptomatic people.
Hypothesis: The TransDot test will achieve a sensitivity of > 90% for TB disease, in a training set of people suspected of having TB disease, and be validated (achieve similarly high sensitivity) subsequently in a prospective test set of people suspected of having TB disease, when compared to a composite gold standard of sputum culture, smear, GeneXpert, chest X-ray, TB symptoms and TB treatment response.
Objectives: The overall objective of the study is to incorporate a six-marker serum signature into a multiplex UCP-LFA format, referred to as TransDot, for finger-prick blood testing. The end point of the study is the accuracy (sensitivity and specificity) of the UCP-LFA TransDot test on finger-prick blood for active TB and will be prospectively compared against gold standard composite diagnostic criteria (GeneXpert, MGIT culture, TB sputum smear, CXR, TB symptom screen and response to TB treatment).
Primary: The primary outcome of interest will be accuracy, sensitivity and specificity of the TransDot finger-prick test when compared with the composite gold standard tests.
|Condition or disease||Intervention/treatment|
|Pulmonary Tuberculosis||Diagnostic Test: Trans-Dot point-of-care test|
Protocol Summary Title: Evaluation of host biomarker-based point-of-care tests for targeted screening for active TB (Screen TB)
Population: A total of 800 people presenting at primary health care clinics with presumed active pulmonary tuberculosis, aged 18 to 70 years, male or female gender, will be recruited. They should be willing to give informed, written consent, including consent for HIV testing. They should have symptoms that could be compatible with active TB (cough > two weeks, plus at least one of the following: fever, weight loss, haemoptysis and night sweats). Participants should not have been on TB treatment for the past 90 days and should not have received immune suppressive therapy, be known with alcohol of drug abuse, have a haemoglobin level <9g/dl or be pregnant or breastfeeding. HIV co-infection is not an exclusion criterion. Participants will be recruited from primary health care clinics in Cape Town, South Africa, Windhoek in Namibia, Addis Ababa in Ethiopia, Banjul in The Gambia and Kampala in Uganda.
Number of Sites: Five sites
Study Duration: 3 years
Subject Duration: 18 months for TB cases, 2 months for non-TB cases
The overall objective of the study is to incorporate a six-marker serum signature into a multiplex UCP-LFA format, referred to as TransDot, for finger-prick blood testing. The end point of the study is the accuracy (sensitivity and specificity) of the UCP-LFA TransDot test on finger-prick blood for active TB and will be prospectively compared against gold standard composite diagnostic criteria (GeneXpert, MGIT culture, TB sputum smear, CXR, TB symptom screen and response to TB treatment).
|Study Type :||Observational|
|Estimated Enrollment :||800 participants|
|Official Title:||Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB|
|Actual Study Start Date :||May 2, 2016|
|Estimated Primary Completion Date :||June 30, 2019|
|Estimated Study Completion Date :||June 30, 2019|
First 500 participants recruited for the Training Set:
Subsequent 300 participants to be used for the Test Set:
Diagnostic Test: Trans-Dot point-of-care test
Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.
Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response.
- Diagnostic performance of the TransDot finger-prick test [ Time Frame: 3 years ]The primary outcome of interest will be accuracy, sensitivity and specificity of the TransDot finger-prick test when compared with the composite gold standard tests.
- POC TransDOT test versus lab-based tests [ Time Frame: 3 years ]To evaluate the agreement between the POC TransDot test and laboratory based ELISAs first (both on serum), and subsequently between POC TransDot (on fingerprick blood) and laboratory based TransDot (on serum).
- TransDOT as treatment response marker [ Time Frame: 3 years ]To investigate the utility of a TransDot test at month 2 and month 6 as a marker of treatment response.
- Identification of additional host marker signatures [ Time Frame: 3 years ]To identify additional host marker signatures that can be utilized for future improvement of diagnostic tests in the TransDot format or other point-of care tests that might become available in the future
- Evaluation of the serum signature's underlying biological processes [ Time Frame: 3 years ]To evaluate the biological processes (cell-based immune profile and components) underlying the six-marker serum signature model during TB disease and treatment response. In parallel, the peripheral profile will compare this to the corresponding profile at the lung infection site.
- Optimisation of ultra-sensitive TB culture techniques [ Time Frame: 3 years ]To refine and optimise ultra-sensitive TB culture techniques on sputum and compare these to standard techniques and the TransDot test results, at baseline and month 6.
- Biomarker Biorepository Samples [ Time Frame: 3 years ]To collect appropriate additional host samples for future biomarker research
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03350048
|Armauer Hansen Research Institute|
|Addis Ababa, Ethiopia|
|Medical Research Council The Gambia|
|European Research and Project Office GmbH|
|Saarbrücken, Saarland, Germany, 66123|
|LINQ Management GmbH|
|Berlin, Germany, 14057|
|University of Namibia|
|Windhoek, Namibia, 13301|
|The European & Developing Countries Clinical Trials Partnership Association (EDCTP)|
|The Hague, South Holland, Netherlands, 2593 HW|
|Leiden University Medical Center (Academisch Ziekenhuis Leiden, LUMC)|
|Leiden, Netherlands, 2333 ZA|
|Cape Town, Western Cape, South Africa, 7505|
|London School of Hygiene and Tropical Medicine|
|London, United Kingdom, WC1E 7HT|
|Principal Investigator:||Gerhard Walzl, PhD, MD||Head of Department of Biomedical Sciences|